Recent Press Releases

Drug Delivery Technologies Market Forecast 2014-2024

LONDON, Oct. 20, 2014 /PRNewswire/ -- Report Details Drug Delivery Technologies - new study showing you trends, R&D progress, and predicted revenuesWhere is the drug delivery technologies market...

Stratamark®, a New Gel, Is First Topical Medical Device For Prevention and Treatment of Stretch Marks

Breakthrough Product Clinically Proven to Allow Skin to Normalize Collagen Synthesis Cycle TORONTO, Oct. 21, 2014 /CNW/ -- 65-75% of women are affected by stretch marks during pregnancy, developing...

Study Shows Feasibility of Treating Clostridium difficile Infection With Oral Administration of Frozen Encapsulated Fecal Material

EMBARGOED FOR RELEASE: 2 P.M. (CT) SATURDAY, OCTOBER 11, 2014 Media Advisory: To contact Ilan Youngster, M.D., M.M.Sc., call Noah Brown at 617- 643-3907 or email nbrown9@partners.org. To place an...

Design of micro and nanoparticles to improve treatments for Alzheimer's and Parkinson's

At the Faculty of Pharmacy of the UPV/EHU-University of the Basque Country encapsulation techniques are being developed to deliver correctly and effectively certain drugs Enara Herran, a researcher...

Portal Instruments Completes Landmark $11 Million Series A Financing To Develop Innovative Drug Delivery Platform

CAMBRIDGE, Mass., Oct. 15, 2014 /PRNewswire/ -- Portal Instruments, Inc., a new dynamic, emerging leader in the development of innovative drug delivery systems, announced today that it has completed...

Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)

CAMBRIDGE, Mass.--()--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today six-month clinical data from its ongoing Phase 2 open-label...

Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at 10th Oligonucleotide Therapeutics Society (OTS) Meeting

– Additional Phase 1 Clinical Results with ALN-TTRsc and Results from Pre-Clinical Chronic Toxicology Studies Confirm Clinical Activity and Wide Therapeutic Index – – ALN-GO1, an...

Intersect ENT Announces Publication Of Positive Data From Three Studies Of Company's Drug-Eluting Sinus Implants

MENLO PARK, Calif., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today...

Icon Bioscience Reports Last Patient Out in Its Phase 3 Study of IBI-10090 as a Dropless, Sustained-Released Therapeutic for Inflammation Associated with Cataract Surgery

IBI-10090 Is The First Drug Candidate Utilizing the Verisome® Delivery Technology October 06, 2014 08:48 AM Eastern Daylight Time SUNNYVALE, Calif.--(BUSINESS WIRE)--Icon Bioscience, Inc., a...

IBN develops green tea-based 'missiles' to kill cancer cells more effectively

Singapore, October 6, 2014 – Green tea has long been known for its anti-oxidant, anti-cancer, anti-aging and anti-microbial properties. A group of researchers from the Institute of...

US Patent Office Institutes Inter Partes Review Brought by MonoSol Rx Against All Claims in Key BDSI BEMA Patent

WARREN, N.J., Oct 06, 2014 (GLOBE NEWSWIRE via COMTEX) -- The United States Patent and Trademark Office (USPTO) has granted MonoSol Rx, LLC's (MonoSol Rx) petition for inter partes review (IPR)...

Flowonix Submits PMA Supplements for Prometra Implantable Pump System

Mount Olive, NJ, September 15, 2014 - Flowonix Medical Inc., a medical device company focused on providing advanced, implantable drug delivery solutions, today announced that it has submitted...

Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research

ALBANY, New York, September 29, 2014 /PRNewswire via COMTEX/ -- ALBANY, New York, September 29, 2014 /PRNewswire/ -- The global implantable drug delivery devices market will notch US$ 21.1 billion by...

U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia

Dual-chamber syringe offers healthcare providers more flexibility during patient office visits First of several anticipated product enhancements to Abilify Maintena September 29, 2014 09:01...

Alnylam Initiates EXPLORE, a Prospective Observational Study of Patients with Hepatic Porphyrias

CAMBRIDGE, Mass., Oct 01, 2014 (BUSINESS WIRE) -- Alnylam Pharmaceuticals, Inc. ALNY, -0.64% a leading RNAi therapeutics company, and collaborators from the American Porphyria Consortium and The...

Allergan Announces FDA Approves Revised Indication for OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema

September 29, 2014 09:00 AM Eastern Daylight Time IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved...

Novaliq GmbH Reports Positive Results from CyclASol® (Cyclosporin Solution) Eye Drops Repeated and Ascending Dose Phase 1 Study

CyclASol® (cyclosporin solution formulation in the semi-fluorinated alkane vehicle F4H5) eye drops are safe and well-tolerated CyclASol® is the first and only clear solution based eye drop...

Titan Pharmaceuticals Announces Enrollment Reaches Halfway Mark in Phase 3 Study of Probuphine for Opioid Dependence

September 23, 2014: 07:00 AM ET Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that patient enrollment in the Phase 3 study of Probuphine®, the company's investigational subdermal...

Flowonix Submits PMA Supplements for Prometra® Implantable Pump System

Mount Olive, NJ, September 15, 2014 - Flowonix Medical Inc., a medical device company focused on providing advanced, implantable drug delivery solutions, today announced that it has submitted...

NxStage Announces FDA Clearance of Single Needle Technology

LAWRENCE, Mass., Sept. 16, 2014 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its single needle technology,...